Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The transcript discusses various deals, projects, acquisitions. We need to see if management conveys that the size of what they are landing now is bigger than before for the same offering, and that this is a pattern, not just one event. Key points: They mention many acquisitions and projects. For example, they mention the Abu Dhabi concession, Zohr, Mauritania, Woolworths, etc. But do they say that these are individually larger than previous similar deals? They talk about "material long-term onshore oil reserves" and "leadership position" but not necessarily comparing to their own past deals in size. They also mention "we have been busy" but not that each new deal is bigger. They also discuss CapEx guidance increasing from $15-17 billion to $16-17 billion due to portfolio additions, but that's not about deal size per se. They mention "we have made big strides in creating a stronger platform for growth" and list many opportunities. But no explicit statement that the size of each new engagement is escalating. There is a mention of "the largest single piece of business" but not really. They talk about "the renewal of 10% of the Abu Dhabi ADCO concession" which is a long-term concession, but they don't say it's bigger than previous ones. They also mention "we were awarded a 10% interest in Abu Dhabi's ADCO concession" which is a specific deal, but not compared to past. The question asks: "does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago?" I don't see that. They talk about many different types of deals, but not that the same kind is escalating in size. They also mention "we have been creative with our portfolio" but not that size is increasing. They mention "we have a stronger and more diversified upstream portfolio" but that's about diversification, not size. They also mention "we have been working systemically to a plan to rebase our capital and cash spend" and "rebalancing" but that's about financials. No clear statement of escalation in unit size. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.